Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management

Leading experts offer insights into colorectal cancer, including its prevalence, staging, and the current landscape of treatment options.

Arvind Dasari, MD, MS, outlines the evolution of colorectal cancer screening, addressing historical challenges, and the development of non-invasive screening techniques.

Experts outline circulating tumor (ct) DNA analysis, detailing the two main techniques and their respective advantages and disadvantages.

The key opinion leaders share their approaches for communicating about circulating tumor DNA and minimal residual disease to patients, emphasizing the significance of ctDNA testing in detecting MRD.

The panel examines recent studies from the INTERCEPT program investigating the utility of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection in colorectal cancer (CRC).

Key opinion leaders analyze recent findings from the BESPOKE study.

Medical experts examine how recent data on circulating tumor DNA-based minimal residual disease testing may impact the clinical management and treatment of colorectal cancer.

Key opinion leaders evaluate the selection of available assays and platforms in relation to specific clinical objectives.

Panelists explore the clinical value of circulating tumor DNA testing at various stages of the colorectal cancer treatment journey, with a focus on optimal testing timelines.

Panelists analyze observed obstacles to implementing routine circulating tumor DNA testing as a standard of care, while offering strategies to overcome these challenges.

The panel examines a clinical scenario, detailing their approach to circulating tumor DNA testing, including turnaround times, and providing insights on patient counseling.

Medical professionals explore methods for integrating circulating tumor DNA results with radiographic and pathologic findings to optimize patient care.

The panel examines challenges in interpreting circulating tumor DNA results and their impact on clinical decision-making processes.

Medical professionals analyze gaps in current colorectal cancer patient care, with a focus on minimal residual disease testing.

Panelists offer concluding perspectives on the future role of circulating tumor DNA in colorectal cancer management.